Pulse Biosciences, Inc

PLSE Healthcare Medical Instruments & Supplies

Pulse Biosciences, Inc’s revenue for fiscal 2025 (year ended December 2025) was $350,000.00, down 50.0% from fiscal 2022.

Revenue
+359.3%
EPS
−10.3%
Free cash flow
−1,180.5%

Quarter to September 2026, against a year earlier

52.32 0.75 −1.41%
Market cap
$3.9B
P/E
0.0×
Fwd P/E
−38.1×
Dividend yield
—
F-score
n/a
Altman Z
31.41
Beneish M
n/a
Dividend safety
n/a
Sep '26 From the 10-Q filed 5 Nov Jun '26 Mar '26 Dec '25 Older periods
ROE
(60.67%) (78.49%) (80.72%) (74.45%)

+8 more TTM periods

ROA
(54.01%) (67.90%) (69.36%) (64.12%)
ROIC
(37.01%) 0.00% 0.00% 0.00%
Return on Tangible Assets
(46.59%) (83.58%) (119.59%) (95.08%)
Average Days of Receivables
72.56 37.58 77.23 165.03
Free Cash Flow per Share
(3.00) (0.89) (0.82) (0.81)
Free Cash Flow
(216.07) (61.39) (55.50) (54.44)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026